What is a unique FDA approval indication for celecoxib?

Celecoxib has a unique FDA approval indication for familial adenomatous polyposis (FAP) because it is specifically indicated for the management of this genetic condition. FAP is characterized by the development of numerous polyps in the colon and rectum, which have a high risk of progressing to colorectal cancer. The use of celecoxib in FAP patients is based on its ability to reduce the number of polyps, thereby potentially decreasing the risk of cancer development in individuals with this hereditary condition.

In contrast, the other options listed, such as osteoarthritis, acute pain, and rheumatoid arthritis, are common indications for celecoxib's use but are not unique to this medication. These conditions are treated with various other anti-inflammatory medications as well, and consequently, they do not stand out as a distinctive FDA approval indication for celecoxib.